13F HOLDINGS REPORT
BAKER BROS. ADVISORS LP
Quarter ended Q3 2023 · Filed August 14, 2023 · Accession 0001104659-23-091343
Total Value
$17.28B
Positions
107
Other Managers
0
Confidential Omitted
No
Holdings (107)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Seagen Inc. | SE | 44,554,162 | $8.57B | 49.63% |
| 2 | Incyte Corporation | INCY | 36,178,056 | $2.25B | 13.03% |
| 3 | BeiGene, Ltd. | BEIGF | 11,668,897 | $2.08B | 12.04% |
| 4 | ACADIA Pharmaceuticals Inc. | ACAD | 42,864,612 | $1.03B | 5.94% |
| 5 | Madrigal Pharmaceuticals, Inc. | MDGL | 1,545,113 | $356.9M | 2.07% |
| 6 | BioMarin Pharmaceutical Inc. | BMRN | 3,810,248 | $330.3M | 1.91% |
| 7 | Immunocore Holdings plc | IMCR | 2,520,731 | $151.1M | 0.87% |
| 8 | Invitae Corporation | 46185LAD5 | 300,000,000 | $135.0M | 0.78% |
| 9 | Kodiak Sciences Inc. | KOD | 17,310,490 | $119.4M | 0.69% |
| 10 | Akero Therapeutics, Inc. | 00973Y108 | 2,368,378 | $110.6M | 0.64% |
| 11 | argenx SE | ARGX | 280,159 | $109.2M | 0.63% |
| 12 | Rhythm Pharmaceuticals, Inc. | RYTM | 6,498,267 | $107.2M | 0.62% |
| 13 | Replimune Group, Inc. | REPL | 4,578,280 | $106.3M | 0.62% |
| 14 | AbCellera Biologics Inc. | ABCL | 16,450,180 | $106.3M | 0.62% |
| 15 | Kymera Therapeutics, Inc. | KYMR | 4,375,340 | $100.6M | 0.58% |
| 16 | Roivant Sciences Ltd. | ROIV | 9,428,592 | $95.0M | 0.55% |
| 17 | BioCryst Pharmaceuticals, Inc. | BCRX | 12,710,818 | $89.5M | 0.52% |
| 18 | SpringWorks Therapeutics, Inc. | 85205L107 | 2,999,846 | $78.7M | 0.46% |
| 19 | Entrada Therapeutics, Inc. | TRDA | 4,865,819 | $73.7M | 0.43% |
| 20 | Revolution Medicines, Inc. | RVMDW | 2,691,493 | $72.0M | 0.42% |
| 21 | Immatics N.V. | IMTX | 5,640,816 | $65.1M | 0.38% |
| 22 | Chinook Therapeutics, Inc. | 16961L106 | 1,455,202 | $55.9M | 0.32% |
| 23 | Mirati Therapeutics, Inc. | 60468T105 | 1,409,784 | $50.9M | 0.29% |
| 24 | DICE Therapeutics, Inc. | 23345J104 | 1,035,786 | $48.1M | 0.28% |
| 25 | Biomea Fusion, Inc. | BMEA | 2,108,949 | $46.3M | 0.27% |
| 26 | Prelude Therapeutics Inc. | PRLD | 10,123,824 | $45.6M | 0.26% |
| 27 | Denali Therapeutics Inc. | DNLI | 1,455,322 | $42.9M | 0.25% |
| 28 | Kiniksa Pharmaceuticals, Ltd. | KNSA | 2,809,577 | $39.6M | 0.23% |
| 29 | Cerus Corporation | CERS | 16,067,558 | $39.5M | 0.23% |
| 30 | Nurix Therapeutics, Inc. | NRIX | 3,882,125 | $38.8M | 0.22% |
| 31 | Ultragenyx Pharmaceutical Inc. | RARE | 783,059 | $36.1M | 0.21% |
| 32 | Aerovate Therapeutics, Inc. | 008064107 | 1,963,479 | $33.7M | 0.19% |
| 33 | IGM Biosciences, Inc. | 449585108 | 3,157,210 | $29.1M | 0.17% |
| 34 | Xenon Pharmaceuticals Inc. | XENE | 751,639 | $28.9M | 0.17% |
| 35 | ImmunoGen, Inc. | 45253H101 | 1,520,097 | $28.7M | 0.17% |
| 36 | DBV Technologies S.A. | DBVTF | 14,614,264 | $27.8M | 0.16% |
| 37 | Verve Therapeutics, Inc. | 92539P101 | 1,416,530 | $26.6M | 0.15% |
| 38 | 2seventy bio, Inc. | 901384107 | 2,497,526 | $25.3M | 0.15% |
| 39 | IDEAYA Biosciences, Inc. | IDYA | 1,062,123 | $25.0M | 0.14% |
| 40 | Stoke Therapeutics, Inc. | STOK | 2,130,238 | $22.6M | 0.13% |
| 41 | Bicycle Therapeutics plc | BCYC | 843,814 | $21.5M | 0.12% |
| 42 | Monte Rosa Therapeutics, Inc. | GLUE | 3,023,951 | $20.7M | 0.12% |
| 43 | Cabaletta Bio, Inc. | CABA | 1,594,000 | $20.6M | 0.12% |
| 44 | Krystal Biotech, Inc. | KRYS | 169,934 | $20.0M | 0.12% |
| 45 | Summit Therapeutics Inc. | SMMT | 6,304,705 | $15.8M | 0.09% |
| 46 | AnaptysBio, Inc. | ANABV | 775,924 | $15.8M | 0.09% |
| 47 | Prime Medicine, Inc. | PRME | 1,028,466 | $15.1M | 0.09% |
| 48 | Pacific Biosciences of California, Inc. | 69404D108 | 1,127,782 | $15.0M | 0.09% |
| 49 | Relay Therapeutics, Inc. | RLAY | 1,160,117 | $14.6M | 0.08% |
| 50 | ARS Pharmaceuticals, Inc. | SPRY | 2,006,451 | $13.4M | 0.08% |
| 51 | Day One Biopharmaceuticals, Inc. | DAWN | 1,000,000 | $11.9M | 0.07% |
| 52 | Sana Biotechnology, Inc. | SANA | 2,000,000 | $11.9M | 0.07% |
| 53 | Cogent Biosciences, Inc. | COGT | 979,600 | $11.6M | 0.07% |
| 54 | POINT Biopharma Global Inc. | 730541109 | 1,169,103 | $10.6M | 0.06% |
| 55 | Adaptimmune Therapeutics plc | ADTI | 10,969,282 | $10.1M | 0.06% |
| 56 | Invitae Corporation | 46185L103 | 8,881,104 | $10.0M | 0.06% |
| 57 | Verastem, Inc. | VSTM | 1,336,485 | $9.9M | 0.06% |
| 58 | Geron Corporation | GERN | 3,061,224 | $9.8M | 0.06% |
| 59 | Heron Therapeutics, Inc. | HRTX | 8,131,678 | $9.4M | 0.05% |
| 60 | Athira Pharma, Inc. | 04746L104 | 3,153,807 | $9.3M | 0.05% |
| 61 | Avidity Biosciences, Inc. | 05370A108 | 799,451 | $8.9M | 0.05% |
| 62 | bluebird bio, Inc. | 09609G100 | 2,499,715 | $8.2M | 0.05% |
| 63 | Fate Therapeutics, Inc. | FATE | 1,671,717 | $8.0M | 0.05% |
| 64 | Allogene Therapeutics, Inc. | ALLO | 1,576,901 | $7.8M | 0.05% |
| 65 | Opthea Limited | OPTEY | 2,691,391 | $7.5M | 0.04% |
| 66 | Insmed Incorporated | INSM | 343,000 | $7.2M | 0.04% |
| 67 | TScan Therapeutics, Inc. | TCRX | 2,784,792 | $7.0M | 0.04% |
| 68 | Aadi Bioscience, Inc. | WHWK | 989,928 | $6.8M | 0.04% |
| 69 | Sera Prognostics, Inc. | SERA | 1,777,435 | $5.9M | 0.03% |
| 70 | Alector, Inc. | ALEC | 964,851 | $5.8M | 0.03% |
| 71 | Compass Therapeutics, Inc. | CMPX | 1,557,630 | $5.0M | 0.03% |
| 72 | Natera, Inc. | NTRA | 100,000 | $4.9M | 0.03% |
| 73 | MacroGenics, Inc. | MGNX | 892,579 | $4.8M | 0.03% |
| 74 | Mereo BioPharma Group PLC | MREO | 3,554,979 | $4.7M | 0.03% |
| 75 | Aravive, Inc. | 03890D108 | 3,261,224 | $4.1M | 0.02% |
| 76 | Affimed N.V. | N01045108 | 6,596,830 | $3.9M | 0.02% |
| 77 | HOOKIPA Pharma Inc. | HOOK | 4,425,535 | $3.9M | 0.02% |
| 78 | Edgewise Therapeutics, Inc. | EWTX | 500,000 | $3.9M | 0.02% |
| 79 | Gracell Biotechnologies Inc. | 38406L103 | 1,000,000 | $3.8M | 0.02% |
| 80 | Leap Therapeutics, Inc. | CYPH | 1,172,175 | $3.7M | 0.02% |
| 81 | Talis Biomedical Corporation | 87424L207 | 7,624,835 | $3.7M | 0.02% |
| 82 | Century Therapeutics, Inc. | IPSC | 1,149,340 | $3.6M | 0.02% |
| 83 | Mersana Therapeutics, Inc. | 59045L106 | 1,086,115 | $3.6M | 0.02% |
| 84 | Atreca, Inc. | 04965G109 | 3,532,760 | $3.5M | 0.02% |
| 85 | Neoleukin Therapeutics, Inc. | 64049K104 | 3,821,740 | $3.2M | 0.02% |
| 86 | Design Therapeutics, Inc. | DSGN | 500,000 | $3.1M | 0.02% |
| 87 | Xencor, Inc. | XNCR | 123,127 | $3.1M | 0.02% |
| 88 | Instil Bio, Inc. | TIL | 5,273,789 | $2.9M | 0.02% |
| 89 | Tango Therapeutics, Inc. | TNGX | 750,000 | $2.5M | 0.01% |
| 90 | Vaxcyte, Inc. | PCVX | 48,885 | $2.4M | 0.01% |
| 91 | Achilles Therapeutics plc | 00449L102 | 2,557,149 | $2.4M | 0.01% |
| 92 | Vera Therapeutics, Inc. | VERA | 146,464 | $2.4M | 0.01% |
| 93 | Praxis Precision Medicines, Inc. | PRAX | 1,879,915 | $2.2M | 0.01% |
| 94 | Aligos Therapeutics, Inc. | ALGS | 2,076,400 | $2.0M | 0.01% |
| 95 | PMV Pharmaceuticals, Inc. | PMVP | 322,024 | $2.0M | 0.01% |
| 96 | iTeos Therapeutics, Inc. | 46565G104 | 150,346 | $2.0M | 0.01% |
| 97 | Vor Biopharma Inc. | VOR | 633,848 | $2.0M | 0.01% |
| 98 | Kala Pharmaceuticals, Inc. | KALA | 116,213 | $1.7M | 0.01% |
| 99 | Perspective Therapeutics, Inc. | CATX | 2,319,286 | $1.5M | 0.01% |
| 100 | Aeglea BioTherapeutics, Inc. | 00773J103 | 3,410,106 | $1.5M | 0.01% |
| 101 | FibroGen, Inc. | 31572Q808 | 238,084 | $642,827 | 0.00% |
| 102 | Nkarta, Inc. | NKTX | 271,329 | $594,211 | 0.00% |
| 103 | Protara Therapeutics, Inc. | TARA | 199,671 | $477,214 | 0.00% |
| 104 | Genetron Holdings Limited | 37186H100 | 455,306 | $423,480 | 0.00% |
| 105 | Foghorn Therapeutics Inc. | FHTX | 45,027 | $316,990 | 0.00% |
| 106 | Vincerx Pharma, Inc. | VNCE | 225,579 | $293,253 | 0.00% |
| 107 | Surrozen, Inc. | SRZNW | 833,333 | $46,000 | 0.00% |